EU/03/14/1271

Table of contents

About

On 4 June 2014, orphan designation (EU/03/14/1271) was granted by the European Commission to Nordic Nanovector AS, Norway, for 177Lu-tetraxetan-tetulomab for the treatment of follicular lymphoma.

Key facts

Active substance
177Lu-tetraxetan-tetulomab
Disease / condition
Treatment of follicular lymphoma
Date of first decision
04/06/2014
Outcome
Positive
EU designation number
EU/03/14/1271

Sponsor's contact details

Nordic Nanovector AS
Kjelsåsveien 168B
NO-0884 Oslo
Norway
Tel. +47 95 76 68 74
Fax +47 22 58 00 07
E-mail: mail@nordicnanovector.no

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating